MICAL2

Across TCGA pan-cancer cohorts, MICAL2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MICAL2 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MICAL2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MICAL2 expression acts as an unfavorable survival marker.

CCRCC, PDAC, and LSCC are the cancer types where MICAL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.678	0.960	.001	99	view →
PDAC	DFS	Tertile	All	0.325	0.542	.002	14	view →
LSCC	DFS	Median	II,III,IV	0.557	0.808	.014	10	view →
HNSC	OS	Median	All	0.619	0.821	.007	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MICAL2–CCRCC (OS)

Open the CCRCC breakdown →